BTAI:NSD-BioXcel Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 43.14

Change

0.00 (0.00)%

Market Cap

USD 1.05B

Volume

0.49M

Average Target Price

USD 92.30 (+113.95%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

Company Website : http://www.bioxceltherapeutics.com

Address : 555 Long Wharf Drive, New Haven, CT, United States, 06511

Employees : 31

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.64

52 Week High : 71.50

Short Ratio : 2.89

52 Week Low : 3.76

Shorted Shares : 2,302,318

200 Day Moving Average : 41.34

Shorted Shares Previous Month : 2,155,236

50 Day Moving Average : 42.92

Shares Held By Insiders : 485.11%

Short Percentage : 10.00%

Shares Held by Institutions : 28.52%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

N/A

 USD32.18B N/A N/A
MRNA Moderna, Inc

N/A

 USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

N/A

 USD24.87B N/A N/A
RPRX Royalty Pharma plc

N/A

 USD24.33B 36.15 9.83
GMAB Genmab A/S

N/A

 USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

N/A

 USD19.73B N/A N/A
INCY Incyte Corporation

N/A

 USD18.93B 47.64 35.20

ETFs Containing BTAI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 195.28% 93% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 195.28% 93% A 95% A
Trailing 12 Months  
Capital Gain 473.67% 94% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 473.67% 94% A 97% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 85.57% N/A N/A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 85.57% N/A N/A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 139.23% N/A N/A 6% F
Risk Adjusted Return 61.46% N/A N/A 78% C+
Market Capitalization 1.05B 77% C+ 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 17.50 6% F 6% F
Price / Cash Flow Ratio -38.44 90% A- 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -136.53% 22% F 9% F
Return on Invested Capital -102.16% 26% F 9% F
Return on Assets -64.42% 9% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.89 59% F 53% F
Short Percent 17.03% 12% F 13% F
Beta 1.64 42% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.